M. L. Levy (Kenton, UK), D. Price (Norwich, United Kingdom)
Peak inspiratory flow rate and the slope of the inhalation profile in dry powder inhalers (DPI)
M. Broeders, J. Molema, H. Folgering (Groesbeek, The Netherlands)
|  |
Determinants of incorrect inhalation technique in patients with asthma and COPD
A. E. Hesselink, B. W. J. H. Penninx, H. A. H. Wijnhoven, D. M. W. Kriegsman, J. T. M. van Eijk (Amsterdam, Maastricht, The Netherlands; Winston-Salem, United States Of America)
| |
The effect of switching to beclomethasone extra fine aerosol on symptom-free days
D. Price, J. Haughney, M. Duerden (Aberdeen, London, United Kingdom)
| |
Comparison between salbutamol-MAGhaler and terbutaline turbohaler
M. Sturm, B. Bosse, M. Erxleben, W. Fleischer (Mainz, Limburg, Germany)
| |
Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients
R. Hodder, B. Dzyngel, N. M. Fagan, M. R. Maleki-Yazdi (Ottawa, Burlington, Toronto, Canada; Ridgefield, United States Of America)
| |
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients
S. A. Kilfeather, H. H. Ponitz, E. Beck, P. Schmidt, A. L. Lee, I. R. Bowen, C. W. Hesse (Sunderland, Bracknell, Berkshire, Lostwithiel, Cornwall, United Kingdom; Berlin, Rudersdorf, Ingelheim am Rhein, Germany; Graz, Austria)
| |
Hydrofluoroalkane beclomethasone dipropionate extra fine aerosol efficacy response at reduced dose compared to other inhaled corticosteroid treatment regimens
M. Vortkamp, K. Ederle, S. Hader (Borken, Loewenstein, Germany)
| |
Ipratropium bromide HFA propellant inhaler has equivalent safety and efficacy to the marketed CFC propellant inhaler in bronchial asthma
J. Laverty, A. J. Harrison, J. L. Jirou-Najou, M. Spiteri (Stoke-on-Trent, Bracknell, Berkshire, United Kingdom; Reims, France)
| |
Lung targeting of flunisolide is enhanced when delivered as an extra fine HFA aerosol with a built-in spacer
S. Newman, J. Richards, P. Hirst, I. Abramowitz, A. Nolting (Nottingham, United Kingdom; Jersey City, United States Of America)
| |
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients
W. Vincken, F. Gerken, D. M. Moonen, T. A. Banjte, J. J. Viljoen (Brussels, Belgium; Ingelheim am Rhein, Germany; EV Breda, The Netherlands; Bloemfontein, South Africa)
| |
A new nonultra fine BDP HFA 134a formulation: clinical equivalence of efficacy and safety versus CFC formulation
G. Lefrancois, J. P. Rocca-Serra, A. Monici Preti (Courbevoie, Marseille, France; Parma, Italy)
| |
A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with
Y. Hettema, W. Huisman, D. de Vos, E. Wunderink, D. S. Voncken (Haarlem, Nijmegen, The Netherlands)
| |
Breath activated inhaler usage and impact on rescue medication usage in patients with an asthma diagnosis: a prescribing claims study of 2823 patients using a CFC - pMDI and a breath-actuated device
D. Price, G. Mitchell (Aberdeen, Bicester, United Kingdom)
| |